Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(alemtuzumab)
2,700 results
  • Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. [Journal Article]
  • MSMult Scler Relat Disord 2018 Jul 19; 25:95-98
  • Sánchez P, Meca-Lallana V, Vivancos J
  • CONCLUSIONS: Our study, along with similar reports in literature, highlights the need for close monitoring in patients who plan to switch from fingolimod to other treatments because of the risk of severe rebound. The etiopathogenic association between fingolimod and TDLs is not clear, but given the increasing reports of cases it should be taken into account for treatment selection in patients with this type of lesions.
New Search Next